Health Canada Authorizes XFG-Adapted COMIRNATY for the 2026-2027 COVID-19 Season

Health Canada has authorized an Omicron XFG-adapted formulation of the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY, for active immunization against COVID-19 in individuals 6 months of age and older. Pfizer Canada ULC and BioNTech SE announced the authorization on September 17, 2026, describing the update as aligned with public health recommendations for the 2026-2027 respiratory virus season. The change affects both community pharmacy immunizers, who deliver the majority of adult COVID-19 vaccinations in most provinces, and hospital or institutional immunization programs preparing fall and winter vaccination clinics.

Dr. Sean Gardiner, Country Medical Lead for Pfizer Canada, said the updated vaccine "provides Canadians and communities with an important protection tool as the virus continues to evolve." Health Canada's decision draws on the cumulative clinical, non-clinical, and real-world evidence base already established for COMIRNATY rather than a new large-scale efficacy trial specific to the XFG lineage change, consistent with the regulatory pathway Health Canada has used for prior strain updates to COVID-19 vaccines. Pfizer Canada says it has secured sufficient inventory to fulfill its contractual commitments to federal and provincial vaccination programs, and that the vaccine will also be available for purchase through participating pharmacies for individuals who are not eligible under a publicly funded program.

Practice guidance for pharmacists

• Confirm with your provincial or regional vaccine distribution program when XFG-adapted stock will replace or supplement any remaining prior-formulation doses, and hold off promoting the new formulation to patients until confirmed stock is on hand.
• Update pharmacy management and immunization-registry systems with the new product's lot numbers and Notice of Compliance details before administering the first dose, to avoid downstream reporting errors.
• Counsel patients that this is a strain update to the existing vaccine platform, not a new vaccine requiring a separate consent or safety discussion, while still reviewing individual contraindications and prior reaction history at each visit.
• Coordinate timing with flu and RSV immunization offers where co-administration is supported by product monographs and provincial protocols, to reduce the number of separate patient visits.
• Be ready to offer the vaccine as a private-pay option to patients outside publicly funded eligibility criteria who still want the updated formulation, per Pfizer Canada's stated distribution plan.
• Watch for updated NACI guidance specific to the 2026-2027 season, since eligibility and prioritization details may be refined after this authorization.

The authorization follows a now-familiar pattern in which Health Canada updates COVID-19 vaccine formulations to track circulating variants ahead of the fall vaccination season, similar to prior XBB.1.5- and LP.8.1-adapted updates. Provincial and territorial immunization programs are expected to confirm their own rollout timelines and any age- or risk-group prioritization in the coming weeks.